Dynamics of D-serine reflected the recovery course of a patient with rapidly progressive glomerulonephritis

CEN Case Rep. 2019 Nov;8(4):297-300. doi: 10.1007/s13730-019-00411-6. Epub 2019 Jul 29.

Abstract

We experienced a case of a 36-year-old female with rapidly progressive glomerulonephritis (RPGN) due to anti-neutrophil cytoplasmic antibody (ANCA)-associated nephritis and systemic lupus erythematosus (SLE) nephritis. Chiral amino acid metabolomics revealed a prominent profile of D-serine in this patient. At the fulminant period of RPGN, the level of plasma D-serine, a potential biomarker in CKD that reflects actual glomerular filtration ratio (GFR), was extremely high. On the other hand, urinary fractional excretion (FE) of D-serine, which was usually much higher than that of L-isoform, was 0% in this patient. These abnormal D-serine profiles normalized in response to the intensive treatment. Normalizations of blood D-serine levels were in parallel with those of blood creatinine levels and potentially reflect the recovery of GFR. FE of D-serine increased transiently before the normalization of D-serine profile, suggesting that kidney promotes urinary excretion of D-serine for the normalization of plasma D-serine level. These unexplored clinical features of D-serine well reflected the clinical course of this patient. Blood D-serine level can also serve as a biomarker in acute kidney injury (AKI) or RPGN, and, in combination with FE of D-serine, may render the clinical practitioners to judge the efficacy of intensive treatments.

Keywords: Acute kidney injury (AKI); D-serine; Fractional excretion (FE); Rapidly progressive glomerulonephritis (RPGN); Systemic lupus erythematosus (SLE).

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / blood*
  • Adult
  • Antibodies, Antineutrophil Cytoplasmic / blood
  • Creatinine / blood
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / therapeutic use
  • Disease Progression
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Glomerular Filtration Rate / drug effects
  • Glomerulonephritis / immunology*
  • Glomerulonephritis / therapy*
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use
  • Kidney / metabolism*
  • Kidney / pathology
  • Kidney / physiopathology
  • Lupus Nephritis / complications
  • Lupus Nephritis / immunology
  • Mycophenolic Acid / administration & dosage
  • Mycophenolic Acid / therapeutic use
  • Plasma Exchange / methods
  • Prednisolone / administration & dosage
  • Prednisolone / therapeutic use
  • Serine / blood*
  • Serine / urine
  • Treatment Outcome

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Enzyme Inhibitors
  • Glucocorticoids
  • Immunosuppressive Agents
  • Serine
  • Cyclophosphamide
  • Prednisolone
  • Creatinine
  • Mycophenolic Acid